Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Evaluation of Perioperative Myocardial Injury in Patients Undergoing Below-Knee Lower Extremity Surgery

NCT07241572 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2025-09-01
Last updated
2025-12-01

Condition(s) studied

Myocardial IschemiaDiabetes Complication

Investigational drug(s) / intervention(s)

high sensitive Troponin I

high sensitive Troponin I: High sensitive Troponin I used to predict myocardial damage

Study summary

The aim of this observational study was to detect myocardial damage by monitoring high-sensitive troponin I levels in patients undergoing below-knee extremity surgery with peripheral nerve block.

The primary question it aims to answer is:

How effective are peroperative high-sensitive troponin I levels in predicting myocardial damage?

High-sensitive troponin I levels will be monitored intraoperatively and at 24 and 48 hours postoperatively.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients over 18 years of age * Patients undergoing below-knee lower extremity surgery * Patients with ASA classifications I, II, III, and IV * Patients who have consented before the procedure * Patients who are literate and able to give consent Exclusion Criteria: * Patients in whom regional anesthesia is contraindicated * Patients who refuse to participate in the study

Primary outcome measure(s)

  • High sensitive Troponin I — 01.09.2025-10.01.2026
    peroperative High sensitive Troponin I
  • High sensitive Troponin I — 01.09.2025-11.01.2026
    postoperative 24th hour High sensitive Troponin I
  • High sensitive Troponin I — 01.09.2025-12.01.2026
    postoperative 48th hour High sensitive Troponin I

Trial sites (1)

FacilityCityRegionStatus
Ankara Bilkent City Hospital Ankara Turkey (Türkiye) Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07241572 on ClinicalTrials.gov ↗ ← All trials in Turkey